| Citation: |
National Center of Gerontology, Chinese Society of Geriatrics, Diabetes Professional Committee of Chinese Aging Well Association. Guideline for the Management of Diabetes Mellitus in the Elderly in China (2024 edition)[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 771-800. DOI: 10.12290/xhyxzz.2024-0347
|
With the deepening of aging in China, the prevalence of diabetes in older people has increased noticeably, and standardized diabetes management is critical for improving clinical outcomes of diabetes in older people. In 2021, the National Center of Gerontology, Chinese Society of Geriatrics, and Diabetes Professional Committee of Chinese Aging Well Association organized experts to write the first guideline for diabetesdiagnosis and treatment in older people in China, the Guideline for the Management of Diabetes Mellitus in the Elderly in China (2021 edition). The guideline emphasizes that older patients with diabetes are a highly heterogeneous group requiring comprehensive assessment and stratified and individualized management strategies. The guideline proposes simple treatments and de-intensified treatment strategies for older patients with diabetes. This edition of the guideline provides clinicians with practical and operable clinical guidance, thus greatly contributing to the comprehensive and full-cycle standardized management of older patients with diabetes in China and promoting the extensive development of clinical and basic research on diabetes in older people and related fields. In the past 3 years, evidence-based medicine for older patients with diabetes and related fields has further advanced, and new treatment concepts, drugs, and technologies have been developed. The guideline editorial committee promptly updated the first edition of the guideline and compiled the Guideline for the Management of Diabetes Mellitus in the Elderly in China (2024 edition). More precise management paths for older patients with diabetes are proposed, for achieving continued standardization of the management of older Chinese patients with diabetes and improving their clinical outcomes.
| [1] |
中华人民共和国民政部. 2021年民政事业发展统计公报[EB/OL]. (2022-08-26)[2023-11-01]. https://www.mca.gov.cn/n156/n189/index.html.
|
| [2] |
LeRoith D, Biessels G J, Braithwaite S S, et al. Treatment of diabetes in old eradults: an Endocrine Society clinical practice guideline[J]. J Clin Endocrinol Metab, 2019, 104(5): 1520-1574. DOI: 10.1210/jc.2019-00198
|
| [3] |
国务院办公厅. 中国防治慢性病中长期规划(2017—2025年)[EB/OL]. (2017-02-14)[2023-11-01]. https://www.forestry.gov.cn/c/www/gwywj/56699.jhtml.
|
| [4] |
国家老年医学中心, 中华医学会老年医学分会, 中国老年保健协会糖尿病专业委员会. 中国老年糖尿病诊疗指南(2021年版)[J]. 中华糖尿病杂志, 2021, 13(1): 14-46.
|
| [5] |
中国老年2型糖尿病防治临床指南编写组, 中国老年医学学会老年内分泌代谢分会, 中国老年保健医学研究会老年内分泌与代谢分会, 等. 中国老年2型糖尿病防治临床指南(2022年版)[J]. 中华内科杂志, 2022, 61(1): 12-50. DOI: 10.3760/cma.j.cn112138-20211027-00751
|
| [6] |
Wang L, Peng W, Zhao Z, et al. Prevalence and treatment of diabetesin China, 2013—2018[J]. JAMA, 2021, 326(24): 2498-2506. DOI: 10.1001/jama.2021.22208
|
| [7] |
Sinclair A, Saeedi P, Kaundal A, et al. Diabetes and global ageing among 65-99-year-old adults: findings from the International Diabetes Federation Diabetes Atlas, 9 (th) edition[J]. Diabetes Res Clin Pract, 2020, 162: 108078. DOI: 10.1016/j.diabres.2020.108078
|
| [8] |
Li Y, Teng D, Shi X, et al. Prevalence of diabetes recordedin mainland China using2018 diagnosticcriteria from the American Diabetes Association: national cross sectional study[J]. BMJ, 2020, 369: m997.
|
| [9] |
Bragg F, Holmes M V, Iona A, et al. Association between diabetes and cause-specific mortalityin rural and urban areas of China[J]. JAMA, 2017, 317 (3): 280-289. DOI: 10.1001/jama.2016.19720
|
| [10] |
Barnett K N, McMurdo M E, Ogston S A, et al. Mortality in people diagnosed with type 2 diabetesatanolderage: a systematic review[J]. Age Ageing, 2006, 35(5): 463-468. DOI: 10.1093/ageing/afl019
|
| [11] |
Ji L, Hu D, Pan C, et al. Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients[J]. Am J Med, 2013, 126(10): 925. e11-e22. DOI: 10.1016/j.amjmed.2013.02.035
|
| [12] |
World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviatedreport of a WHO consultation[M]. Geneva: World Health Organization, 2011.
|
| [13] |
Picón M J, Murri M, Mu-oz A, et al. Hemoglobin A1c versus oral glucosetolerancetestin postpartum diabetes screening[J]. Diabetes Care, 2012, 35(8): 1648-1653. DOI: 10.2337/dc11-2111
|
| [14] |
Huang S H, Huang P J, Li J Y, et al. Hemoglobin A1c levels associated with age and gender in Taiwanese adults without prior diagnosis with diabetes[J]. Int J Environ Res Public Health, 2021, 18 (7): 3390. DOI: 10.3390/ijerph18073390
|
| [15] |
Lin L, Wang A, He Y, et al. Effects of the hemoglobin glycationindex on hyperglycemia diagnosis: results from the REACTION study[J]. Diabetes Res Clin Pract, 2021, 180: 109039. DOI: 10.1016/j.diabres.2021.109039
|
| [16] |
Kotwal A, Haddox C, Block M, et al. Immune check point inhibitors: an emerging cause of insulin-dependent diabetes[J]. BMJ Open Diabetes Res Care, 2019, 7(1): e000591. DOI: 10.1136/bmjdrc-2018-000591
|
| [17] |
Aggarwal G, Kamada P, Chari ST. Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers[J]. Pancreas, 2013, 42(2): 198-201. DOI: 10.1097/MPA.0b013e3182592c96
|
| [18] |
Andersen D K, Korc M, Petersen G M, et al. Diabetes, pancreatogenic diabetes, and pancreatic cancer[J]. Diabetes, 2017, 66 (5): 1103-1110. DOI: 10.2337/db16-1477
|
| [19] |
Crandall J P, Mather K, Rajpathak S N, et al. Statin use andrisk ofdeveloping diabetes: results from the Diabetes Prevention Program[J]. BMJ Open Diabetes Res Care, 2017, 5(1): e000438. DOI: 10.1136/bmjdrc-2017-000438
|
| [20] |
胡秀英, 龙纳, 吴琳娜, 等. 中国老年人健康综合功能评价量表的研制[J]. 四川大学学报(医学版), 2013, 44(4): 610-613.
|
| [21] |
樊瑾, 于普林, 李小鹰. 中国健康老年人标准(2013) 解读2——健康评估方法[J]. 中华老年医学杂志, 2014, 33(1): 1-3. DOI: 10.3760/cma.j.issn.0254-9026.2014.01.001
|
| [22] |
茅范贞, 陈俊泽, 苏彩秀, 等. 老年健康功能多维评定量表的研制[J]. 中国卫生统计, 2015, 32(3): 379-382.
|
| [23] |
Katz S C, Ford A B, Moskowitz R W, et al. Studies of illnessin the aged. The index of Adl: a standardized measure of biological and psychosocial function[J]. JAMA, 1963, 185(12): 914-919. DOI: 10.1001/jama.1963.03060120024016
|
| [24] |
Lawton M P, Brody E M. Assessment of older people: self-maintaining and instrumental activities of daily living[J]. Gerontologist, 1969, 9(3): 179-186.
|
| [25] |
Liu Y, Xiao X, Peng C, et al. Development and implementation of couple-based collaborative management model of type 2 diabetes mellitus for community-dwelling Chinese older adults: a pilot randomized trial[J]. Front Public Health, 2021, 9: 686282. DOI: 10.3389/fpubh.2021.686282
|
| [26] |
Li F, Guo S, Gong W, et al. Self-management of diabetes for empty nest older adults: a randomized controlled trial[J]. West J Nurs Res, 2023, 45 (10): 921-931. DOI: 10.1177/01939459231191599
|
| [27] |
Sng G G R, Tung J Y M, Lim D Y Z, et al. Potential and pitfalls of ChatGPT and natural-language artificial intelligence models for diabetes education[J]. Diabetes Care, 2023, 46 (5): e103-e105. DOI: 10.2337/dc23-0197
|
| [28] |
Battelino T, Danne T, Bergenstal RM, et al. Clinica ltargets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range[J]. . Diabetes Care, 2019, 42(8): 1593-1603. DOI: 10.2337/dci19-0028
|
| [29] |
American Diabetes Association. (6) Glycemic targets[J]. Diabetes Care, 2015, 38 Suppl: S33-S40.
|
| [30] |
Rahi B, Morais JA, Gaudreau P, et al. Energy and protein intakes and their association with a declinein functional capacity among diabetic older adults from the NuAge cohort[J]. Eur J Nutr, 2016, 55 (4): 1729-1739. DOI: 10.1007/s00394-015-0991-1
|
| [31] |
Op den Kamp C M, Langen R C, Haegens A, et al. Muscle atrophyin cachexia: can dietary protein tip the balance?[J]. Curr Opin Clin Nutr Metab Care, 2009, 12 (6): 611-616. DOI: 10.1097/MCO.0b013e3283319399
|
| [32] |
Markova M, Pivovarova O, Hornemann S, et al. Isocaloric diets highin animal or plant proteinreduce liver fat and inflammation in individuals with type 2 diabetes[J]. Gastroenterology, 2017, 152 (3): 571-585.e8. DOI: 10.1053/j.gastro.2016.10.007
|
| [33] |
Shukla A P, Dickison M, Coughlin N, et al. The impact of food order on postprandial glycaemic excursionsin prediabetes[J]. Diabetes Obes Metab, 2019, 21 (2): 377-381. DOI: 10.1111/dom.13503
|
| [34] |
Turnbull P J, Sinclair A J. Evaluation of nutritional status and its relationship with functional status in older citizens with diabetes mellitus using the mini nutritional assessment(MNA)tool-a preliminary investigation[J]. J Nutr Health Aging, 2002, 6(3): 185-189.
|
| [35] |
Tan S, Li W, Wang J. Effects of six months of combined aerobic and resistance training for elderly patients with a long history of type 2 diabetes[J]. J Sports Sci Med, 2012, 11(3): 495-501.
|
| [36] |
Lu X, Zhao C. Exercise and type 1 diabetes[J]. Adv Exp Med Biol, 2020, 1228: 107-121.
|
| [37] |
Sampath Kumar A, Maiya A G, Shastry B A, et al. Exercise and insulin resistance in type 2 diabetes mellitus: a systematic review and meta-analysis[J]. Ann Phys Rehabil Med, 2019, 62 (2): 98-103. DOI: 10.1016/j.rehab.2018.11.001
|
| [38] |
Dunstan D W, Daly R M, Owen N, et al. High-intensity resistance training improves glycemic control in older patients with type 2 diabetes[J]. Diabetes Care, 2002, 25 (10): 1729-1736. DOI: 10.2337/diacare.25.10.1729
|
| [39] |
Jansson A K, Chan L X, Lubans D R, et al. Effect of resistance training on HbA1c in adults with type 2 diabetes mellitus and the moderating effec tof changes in muscular strength: a systematic review and meta analysis[J]. BMJ Open Diabetes Res Care, 2022, 10(2): e002595. DOI: 10.1136/bmjdrc-2021-002595
|
| [40] |
Morrison S, Colberg S R, Mariano M, et al. Balance training reduces falls risk in older individuals with type 2 diabetes[J]. Diabetes Care, 2010, 33 (4): 748-750. DOI: 10.2337/dc09-1699
|
| [41] |
Wang Y, Yan J, Zhang P, et al. Tai Chi Program to improve glucose control and quality of life for the elderly with type 2 diabetes: a Meta-analysis[J]. Inquiry, 2022, 59: 469580211067934. DOI: 10.1177/00469580211067934
|
| [42] |
Chodzko-Zajko W J, Proctor D N, Fiatarone Singh M A, et al. American College of Sports Medicine positionstand. Exerciseand physicalactivityfor older adults[J]. Med Sci Sports Exerc, 2009, 41 (7): 1510-1530. DOI: 10.1249/MSS.0b013e3181a0c95c
|
| [43] |
Kanaley J A, Colberg S R, Corcoran M H, et al. Exercise/physical activity in individuals with type 2 diabetes: a consensus statement from the American College of Sports Medicine[J]. Med Sci Sports Exerc, 2022, 54(2): 353-368. DOI: 10.1249/MSS.0000000000002800
|
| [44] |
Blonde L, Dailey G E, Jabbour S A, et al. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study[J]. Curr Med Res Opin, 2004, 20 (4): 565-572. DOI: 10.1185/030079904125003278
|
| [45] |
二甲双胍临床应用专家共识(2018年版)[J]. 中国糖尿病杂志, 2019, 27(3): 161-173.
|
| [46] |
Wong C W, Leung C S, Leung C P, et al. Association of metformin use with vitamin B (12) deficiency in the institutionalized elderly[J]. Arch Gerontol Geriatr, 2018, 79: 57-62. DOI: 10.1016/j.archger.2018.07.019
|
| [47] |
American Diabetes Association Professional Practice Committee. 13. Older adults: standards of care indiabetes—2024[J]. Diabetes Care, 2024, 47(Suppl1): S244-S257.
|
| [48] |
叶林虎, 贺梅, 赵欣黔, 等. 磺脲类降糖药的潜在药物相互作用研究进展[J]. 中国医院药学杂志, 2018, 38(12): 1333-1337.
|
| [49] |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4): 315-409.
|
| [50] |
Zhang J, Guo L. Effectiveness of acarbosein treating elderly patients with diabetes with postprandial hypotension[J]. J Investig Med, 2017, 65(4): 772-783. DOI: 10.1136/jim-2016-000295
|
| [51] |
Dormandy J A, Charbonnel B, Eckland D J, et al. Secondary prevention of macrovascular events in patients with type 2 diabetesinthe PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial[J]. Lancet, 2005, 366 (9493): 1279-1289. DOI: 10.1016/S0140-6736(05)67528-9
|
| [52] |
Lee M, Saver J L, Liao H W, et al. Pioglitazone for secondary stroke prevention: a systematic review and Meta-analysis[J]. Stroke, 2017, 48(2): 388-393. DOI: 10.1161/STROKEAHA.116.013977
|
| [53] |
Yen C L, Wu C Y, Tsai C Y, et al. Pioglitazone reduces cardiovascular events and dementia butincreases bone fracture in elderly patients with type 2 diabetes mellitus: a national cohort study[J]. Aging (Albany NY), 2023, 15(7): 2721-2733.
|
| [54] |
Phatak H M, Yin D D. Factors associated with the effect-size of thiazolidinedione(TZD) therapy on HbA(1c): a meta-analysis of published randomized clinical trials[J]. Curr Med Res Opin, 2006, 22 (11): 2267-2278. DOI: 10.1185/030079906X148328
|
| [55] |
Schwartz A V, Chen H, Ambrosius W T, et al. Effects of TZD use and discontinuation on fracture rates in ACCORD bone study[J]. J Clin Endocrinol Metab, 2015, 100 (11): 4059-4066. DOI: 10.1210/jc.2015-1215
|
| [56] |
Billington E O, Grey A, Bolland M J. The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis[J]. Diabetologia, 2015, 58(10): 2238-2246. DOI: 10.1007/s00125-015-3660-2
|
| [57] |
Mulvihill E E, Drucker D J. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors[J]. Endocr Rev, 2014, 35(6): 992-1019. DOI: 10.1210/er.2014-1035
|
| [58] |
Scheen A J. The safety of gliptins: updated data in 2018[J]. Expert Opin Drug Saf, 2018, 17 (4): 387-405. DOI: 10.1080/14740338.2018.1444027
|
| [59] |
Stafford S, Elahi D, Meneilly G S. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus[J]. J Am Geriatr Soc, 2011, 59 (6): 1148-1149. DOI: 10.1111/j.1532-5415.2011.03438.x
|
| [60] |
Ledesma G, Umpierrez G E, Morley J E, et al. Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: a randomized trial[J]. Diabetes Obes Metab, 2019, 21(11): 2465-2473. DOI: 10.1111/dom.13829
|
| [61] |
Bethel M A, Engel S S, Green J B, et al. Assessing the safety of sitagliptin in older participants in the trial evaluating cardiovascular outcomes with sitagliptin (TECOS)[J]. Diabetes Care, 2017, 40 (4): 494-501. DOI: 10.2337/dc16-1135
|
| [62] |
Cooper M E, Rosenstock J, Kadowaki T, et al. Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: a prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA-trial[J]. Diabetes Obes Metab, 2020, 22 (7): 1062-1073. DOI: 10.1111/dom.13995
|
| [63] |
Leiter L A, Teoh H, Braunwald E, et al. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial[J]. Diabetes Care, 2015, 38(6): 1145-1153. DOI: 10.2337/dc14-2868
|
| [64] |
Gallo L A, Wright E M, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences[J]. Diab Vasc Dis Res, 2015, 12(2): 78-89. DOI: 10.1177/1479164114561992
|
| [65] |
Lunati M E, Cimino V, Gandolfi A, et al. SGLT2-inhibitors are effective and safe in the elderly: the SOLD study[J]. Pharmacol Res, 2022, 183 : 106396. DOI: 10.1016/j.phrs.2022.106396
|
| [66] |
Tahrani A A, Barnett A H, Bailey C J. SGLT inhibitors in management of diabetes[J]. Lancet Diabetes Endocrinol, 2013, 1(2): 140-151. DOI: 10.1016/S2213-8587(13)70050-0
|
| [67] |
Wiviott S D, Raz I, Bonaca M P, et al. Dapagliflozin and cardiovascular outcomes in type2 diabetes[J]. N Engl J Med, 2019, 380 (4): 347-357. DOI: 10.1056/NEJMoa1812389
|
| [68] |
Neal B, Perkovic V, Mahaffey K W, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med, 2017, 377 (7): 644-657. DOI: 10.1056/NEJMoa1611925
|
| [69] |
Zinman B, Wanner C, Lachin J M, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med, 2015, 373 (22): 2117-2128. DOI: 10.1056/NEJMoa1504720
|
| [70] |
Cannon C P, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes[J]. N Engl J Med, 2020, 383 (15): 1425-1435. DOI: 10.1056/NEJMoa2004967
|
| [71] |
Ji L, Ma J, Li H, et al. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phaseⅢ study[J]. Clin Ther, 2014, 36 (1): 84-100. e9. DOI: 10.1016/j.clinthera.2013.11.002
|
| [72] |
Yabe D, Shiki K, Homma G, et al. Efficacy andsafety of the sodium-glucose co-transporter-2 inhibitor empagliflozinin elderly Japanese adults (≥65-years) with type 2 diabetes: a randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPAELDERLY)[J]. Diabetes Obes Metab, 2023, 25 (12): 3538-3548. DOI: 10.1111/dom.15249
|
| [73] |
Karagiannis T, Tsapas A, Athanasiadou E, et al. GLP- 1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis[J]. Diabetes Res Clin Pract, 2021, 174: 108737. DOI: 10.1016/j.diabres.2021.108737
|
| [74] |
Monteiro P, Bergenstal R M, Toural E, et al. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME-trial[J]. Age Ageing, 2019, 48 (6): 859-866. DOI: 10.1093/ageing/afz096
|
| [75] |
Mahaffey K W, Neal B, Perkovic V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study)[J]. Circulation, 2018, 137 (4): 323-334. DOI: 10.1161/CIRCULATIONAHA.117.032038
|
| [76] |
Cahn A, Mosenzon O, Wiviott SD, et al. Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE-TIMI 58 Study[J]. Diabetes Care, 2020, 43(2): 468-475. DOI: 10.2337/dc19-1476
|
| [77] |
Perkovic V, Jardine M J, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy[J]. N Engl J Med, 2019, 380 (24): 2295-2306. DOI: 10.1056/NEJMoa1811744
|
| [78] |
Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial[J]. Lancet Diabetes Endocrinol, 2019, 7(8): 606-617. DOI: 10.1016/S2213-8587(19)30180-9
|
| [79] |
Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes[J]. N Engl J Med, 2016, 375 (4): 323-334. DOI: 10.1056/NEJMoa1515920
|
| [80] |
The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in patients with chronic kidney disease[J]. N Engl J Med, 2023, 388(2): 117-127. DOI: 10.1056/NEJMoa2204233
|
| [81] |
Heerspink H J L, Stefánsson B V, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease[J]. N Engl J Med, 2020, 383(15): 1436-1446. DOI: 10.1056/NEJMoa2024816
|
| [82] |
Heerspink H J L, Sj-str-m CD, Jongs N, et al. Effects of dapagliflozin on mortalityin patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial[J]. Eur Heart J, 2021, 42 (13): 1216-1227. DOI: 10.1093/eurheartj/ehab094
|
| [83] |
B-hm M, Butler J, Filippatos G, et al. Empagliflozin improves outcomesin patients with heart failure and preserved ejection fraction irrespective of age[J]. J Am Coll Cardiol, 2022, 80 (1): 1-18. DOI: 10.1016/j.jacc.2022.04.040
|
| [84] |
Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction[J]. N Engl J Med, 2021, 385 (16): 1451-1461. DOI: 10.1056/NEJMoa2107038
|
| [85] |
Packer M, Anker S D, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure[J]. N Engl J Med, 2020, 383 (15): 1413-1424. DOI: 10.1056/NEJMoa2022190
|
| [86] |
McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2019, 381(21): 1995-2008. DOI: 10.1056/NEJMoa1911303
|
| [87] |
Peikert A, Martinez FA, Vaduganathan M, et al. Efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction accordingto age: the DELIVER Trial[J]. Circ Heart Fail, 2022, 15(10): e010080.
|
| [88] |
Solomon S D, McMurray J, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction[J]. N Engl J Med, 2022, 387(12): 1089-1098. DOI: 10.1056/NEJMoa2206286
|
| [89] |
Pratley R E, Cannon C P, Cherney D Z I, et al. Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozinin older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial[J]. Lancet Healthy Longev, 2023, 4(4): e143-e154. DOI: 10.1016/S2666-7568(23)00032-6
|
| [90] |
孔德华, 李敬文, 周红. 钠-葡萄糖共转运蛋白2抑制剂对2型糖尿病患者酮症酸中毒影响的Meta分析[J]. 中华糖尿病杂志, 2023, 15(2): 144-151.
|
| [91] |
Kidney Disease: Improving Global Outcomes (KDIGO)Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease[J]. Kidney Int, 2022, 102 (5S): S1-S127.
|
| [92] |
Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists[J]. Diabetes Obes Metab, 2016, 18 (4): 317-332. DOI: 10.1111/dom.12596
|
| [93] |
Singh S, Wright E E Jr, Kwan A Y, et al. Glucagon-like peptide-1 receptor agonists compared with basalinsulins for the treatment of type2 diabetes mellitus: a systematic review and meta-analysis[J]. Diabetes Obes Metab, 2017, 19(2): 228-238. DOI: 10.1111/dom.12805
|
| [94] |
Htike Z Z, Zaccardi F, Papamargaritis D, et al. Efficacy andsafetyof glucagon-like peptide-1 receptor agonists in type2 diabetes: a systematic review and mixed-treatment comparisonanalysis[J]. Diabetes Obes Metab, 2017, 19(4): 524-536. DOI: 10.1111/dom.12849
|
| [95] |
Hamano K, Nishiyama H, Matsui A, et al. Efficacy and safety analyses across 4 subgroups combining low and high ageand body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after26 weeks of treatment[J]. Endocr J, 2017, 64 (4): 449-456. DOI: 10.1507/endocrj.EJ16-0428
|
| [96] |
Raccah D, Miossec P, Esposito V, et al. Efficacy and safety of lixisenatide in elderly (≥65 years old)and very elderly (≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phaseⅢ programme[J]. Diabetes Metab Res Rev, 2015, 31(2): 204-211. DOI: 10.1002/dmrr.2588
|
| [97] |
Bode B W, Brett J, Falahati A, et al. Comparison of the efficacy and tolerability profile of liraglutide, a oncedaily human GLP-1 analog, in patients with type 2 diabetes≥65 and < 65 years of age: a pooled analysis from phase Ⅲ studies[J]. Am J Geriatr Pharmacother, 2011, 9 (6): 423-433. DOI: 10.1016/j.amjopharm.2011.09.007
|
| [98] |
Kristensen S L, R-rth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials[J]. Lancet Diabetes Endocrinol, 2019, 7(10): 776-785. DOI: 10.1016/S2213-8587(19)30249-9
|
| [99] |
Gerstein H C, Colhoun H M, Dagenais G R, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes(REWIND): a double-blind, randomised placebo controlled trial[J]. Lancet, 2019, 394 (10193): 121-130. DOI: 10.1016/S0140-6736(19)31149-3
|
| [100] |
Marso S P, Daniels G H, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2016, 375 (4): 311-322. DOI: 10.1056/NEJMoa1603827
|
| [101] |
Marso S P, Bain S C, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med, 2016, 375 (19): 1834-1844. DOI: 10.1056/NEJMoa1607141
|
| [102] |
Pfeffer M A, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome[J]. N Engl J Med, 2015, 373 (23): 2247-2257. DOI: 10.1056/NEJMoa1509225
|
| [103] |
Holman R R, Bethel M A, Mentz R J, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2017, 377 (13): 1228-1239. DOI: 10.1056/NEJMoa1612917
|
| [104] |
Li C, Luo J, Jiang M, et al. The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: a systematic review and Meta-analysis[J]. Front Pharmacol, 2022, 13 : 838277. DOI: 10.3389/fphar.2022.838277
|
| [105] |
Riley D R, Essa H, Austin P, et al. All-cause mortality andcardiovascular outcomes with sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes[J]. Diabetes Obes Metab, 2023, 25(10): 2897-2909. DOI: 10.1111/dom.15185
|
| [106] |
Sinclair A J, Dashora U, George S, et al. Joint British Diabetes Societies for Inpatient Care (JBDS-IP) Clinical Guideline Inpatient care of the frail older adult with diabetes: an Executive Summary[J]. Diabet Med, 2020, 37(12): 1981-1991. DOI: 10.1111/dme.14341
|
| [107] |
Sodhi M, Rezaeianzadeh R, Kezouh A, et al. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss[J]. JAMA, 2023, 330 (18): 1795-1797. DOI: 10.1001/jama.2023.19574
|
| [108] |
冉兴无, 母义明, 朱大龙, 等. 成人2型糖尿病基础胰岛素临床应用中国专家指导建议(2020版)[J]. 中国糖尿病杂志, 2020, 28 (10): 721-728.
|
| [109] |
Blonde L, Umpierrez G E, Reddy S S, et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan—2022 update[J]. Endocr Pract, 2022, 28(10): 923-1049.
|
| [110] |
Philis-Tsimikas A, Astamirova K, Gupta Y, et al. Similar glycaemiccontrol with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type2 diabetes mellitus[J]. Diabetes Res Clin Pract, 2019, 147: 157-165. DOI: 10.1016/j.diabres.2018.10.024
|
| [111] |
Brunner M, Pieber T, Korsatko S, et al. The distinct prandial and basal pharmacodynamics of IdegAsp observed in younger adults are preserved in elderly subjects with type 1 diabetes[J]. Drugs Aging, 2015, 32(7): 583-590. DOI: 10.1007/s40266-015-0272-y
|
| [112] |
Fulcher G, Mehta R, Fita E G, et al. Efficacy and safety of IDegAsp versus BIAsp 30, both twice daily, in elderly patients with type 2 diabetes: post hoc analysis of two phase 3 randomized controlled BOOST trials[J]. Diabetes Ther, 2019, 10 (1): 107-118. DOI: 10.1007/s13300-018-0531-0
|
| [113] |
Kaneko S, da Rocha Fernandes J D, Yamamoto Y, et al. A Japanese study assessing glycemic control with use of IDegAspco-formulationin patients with type 2 diabetes in clinical practice: the JAGUAR study[J]. Adv Ther, 2021, 38 (3): 1638-1649. DOI: 10.1007/s12325-021-01623-y
|
| [114] |
Wallia A, Molitch M E. Insulin therapy for type 2 diabetes mellitus[J]. JAMA, 2014, 311 (22): 2315-2325. DOI: 10.1001/jama.2014.5951
|
| [115] |
ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2023[J]. Diabetes Care, 2023, 46 (Suppl 1): S140-S157.
|
| [116] |
Handelsman Y, Chovanes C, Dex T, et al. Efficacy and safety of insulin glargine/lixisenatide(iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes[J]. J Diabetes Complications, 2019, 33(3): 236-242. DOI: 10.1016/j.jdiacomp.2018.11.009
|
| [117] |
Billings L K, Agner B, Altuntas Y, et al. The benefit of insulin degludec/liraglutide(IDegLira)compared with basal-bolus insulin therapy is consistent across participant subgroups with type 2 diabetes in the DUAL Ⅶ randomized trial[J]. J Diabetes Sci Technol, 2021, 15 (3): 636-645. DOI: 10.1177/1932296820906888
|
| [118] |
《以二甲双胍为基础的固定复方制剂治疗2型糖尿病专家共识》编写组. 以二甲双胍为基础的固定复方制剂治疗2型糖尿病专家共识[J]. 中华糖尿病杂志, 2022, 14 (12): 1380-1386. DOI: 10.3760/cma.j.cn115791-20220930-00505
|
| [119] |
Bajaj H S, Ye C, Jain E, et al. Glycemic improvement with afixed-dose combination of DPP-4 inhibitor-+-metformin in patients with type 2 diabetes (GIFT study)[J]. Diabetes Obes Metab, 2018, 20 (1): 195-199. DOI: 10.1111/dom.13040
|
| [120] |
Rosenstock J, Aronson R, Grunberger G, et al. Benefits of lixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial[J]. Diabetes Care, 2016, 39 (11): 2026-2035. DOI: 10.2337/dc16-0917
|
| [121] |
Yuan X, Guo X, Zhang J, et al. Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100-U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: results from the LixiLan-L-CN randomized controlled trial[J]. Diabetes Obes Metab, 2022, 24 (11): 2182-2191. DOI: 10.1111/dom.14803
|
| [122] |
Blonde L, Rosenstock J, Del Prato S, et al. Switching to iGlarLixi versus continuing daily or weekly GLP-1 Rain type2 diabetes inadequately controlled by GLP-1Raand oral antihyperglycemic therapy: the LixiLan-G randomized clinical trial[J]. Diabetes Care, 2019, 42(11): 2108-2116. DOI: 10.2337/dc19-1357
|
| [123] |
Wang W, Agner BFR, Luo B, et al. DUAL I China: improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type2 diabetes uncontrolled on oral antidiabetic drugs[J]. J Diabetes, 2022, 14(6): 401-413. DOI: 10.1111/1753-0407.13286
|
| [124] |
Pei Y, Agner B R, Luo B, et al. DUALⅡ China: superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludecin a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin[J]. Diabetes Obes Metab, 2021, 23 (12): 2687-2696. DOI: 10.1111/dom.14522
|
| [125] |
Linjawi S, Bode B W, Chaykin L B, et al. The efficacy of IDegLira (insulin degludec/liraglutide combination) in adults with type2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUALⅢ randomized clinical trial[J]. Diabetes Ther, 2017, 8(1): 101-114. DOI: 10.1007/s13300-016-0218-3
|
| [126] |
Komatsu M, Watada H, Kaneko S, et al. Efficacy and safety of the fixed-ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: a subgroup analysis of two phase Ⅲ trials[J]. J Diabetes Investig, 2021, 12(9): 1610-1618. DOI: 10.1111/jdi.13525
|
| [127] |
Zhang XH, Tian YF, Huang GL, et al. Advances in studies of Chiglitazar Sodium, a novel PPAR panagonist, for the treatment of type 2 diabetes mellitus[J]. Curr Med Sci, 2023, 43 (5): 890-896. DOI: 10.1007/s11596-023-2760-3
|
| [128] |
Toulis K A, Nirantharakumar K, Pourzitaki C, et al. Glucokinase activators for type 2 diabetes: challenges and future developments[J]. Drugs, 2020, 80(5): 467-475. DOI: 10.1007/s40265-020-01278-z
|
| [129] |
Einarson TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic Literature review of scientific evidence from across the worldin 2007 —2017[J]. Cardiovasc Diabetol, 2018, 17(1): 83. DOI: 10.1186/s12933-018-0728-6
|
| [130] |
Sarwar N, Gao P, Seshasai S R, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies[J]. Lancet, 2010, 375 (9733): 2215-2222. DOI: 10.1016/S0140-6736(10)60484-9
|
| [131] |
Lacey B, Lewington S, Clarke R, et al. Age-specific association between blood pressure and vascular and non-vascular chronic diseasesin 0. 5 million adultsin China: a prospective cohort study[J]. Lancet Glob Health, 2018, 6 (6): e641-e649. DOI: 10.1016/S2214-109X(18)30217-1
|
| [132] |
Brunstr-m M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta analyses[J]. BMJ, 2016, 352: i717.
|
| [133] |
Beckett N S, Peters R, Fletcher A E, et al. Treatment of hypertension in patients 80 years of age or older[J]. N Engl J Med, 2008, 358 (18): 1887-1898. DOI: 10.1056/NEJMoa0801369
|
| [134] |
Cushman W C, Evans G W, Byington R P, et al. Effects of intensive blood-pressure controlin type 2 diabetes mellitus[J]. N Engl J Med, 2010, 362 (17): 1575-1585. DOI: 10.1056/NEJMoa1001286
|
| [135] |
Zhang W, Zhang S, Deng Y, et al. Trial of intensive blood-pressure control in older patients with hypertension[J]. N Engl J Med, 2021, 385 (14): 1268-1279. DOI: 10.1056/NEJMoa2111437
|
| [136] |
ElSayed N A, Aleppo G, Aroda V R, et al. 13. Older adults: standards of care in diabetes—2023[J]. Diabetes Care, 2023, 46 (Suppl 1): S216-S229.
|
| [137] |
Weiss J, Freeman M, Low A, et al. Benefits and harms of intensive blood pressure treatment in adults aged 60 years or older: a systematic review and Meta analysis[J]. Ann Intern Med, 2017, 166 (6): 419-429. DOI: 10.7326/M16-1754
|
| [138] |
Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin Ⅱ receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a metaanalysis[J]. JAMA Intern Med, 2014, 174 (5): 773-785. DOI: 10.1001/jamainternmed.2014.348
|
| [139] |
Lindholm L H, Hansson L, Ekbom T, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group[J]. J Hypertens, 2000, 18 (11): 1671-1675.
|
| [140] |
Catalá-López F, Macías Saint-Gerons D, GonzálezBermejo D, et al. Cardiovascular and renal outcomes of renin-angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network Meta-analyses[J]. PLoS Med, 2016, 13 (3): e1001971. DOI: 10.1371/journal.pmed.1001971
|
| [141] |
Elgendy I Y, Huo T, Chik V, et al. Efficacy and safety of angiotensin receptor blockers in older patients: a meta-analysis of randomized trials[J]. Am J Hypertens, 2015, 28 (5): 576-585. DOI: 10.1093/ajh/hpu209
|
| [142] |
血脂异常老年人使用他汀类药物中国专家共识组. 血脂异常老年人使用他汀类药物中国专家共识[J]. 中华内科杂志, 2015, 54 (5): 467-477. DOI: 10.3760/cma.j.issn.0578-1426.2015.05.020
|
| [143] |
海峡两岸医药卫生交流协会老年医学专业委员会. ≥75岁老年患者血脂异常管理的专家共识[J]. 中国心血管杂志, 2020, 25 (3): 201-209.
|
| [144] |
Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statintherapy inolder people: a meta-analysis of individual participant data from 28 randomised controlled trials[J]. Lancet, 2019, 393 (10170): 407-415. DOI: 10.1016/S0140-6736(18)31942-1
|
| [145] |
Heart Protection Study Collaborative Group. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20, 536 high-risk people: a randomised placebo controlled trial[ISRCTN48489393 ][J]. BMC Med, 2005, 3: 6.
|
| [146] |
Olafsdottir E, Aspelund T, Sigurdsson G, et al. Effects of statin medicationon mortality risk associated with type2 diabetes in older persons: the population-based AGESReykjavik Study[J]. BMJ Open, 2011, 1 (1): e000132. DOI: 10.1136/bmjopen-2011-000132
|
| [147] |
Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlledtrial[J]. Lancet, 2003, 361 (9374): 2005-2016. DOI: 10.1016/S0140-6736(03)13636-7
|
| [148] |
Neil H A, DeMicco D A, Luo D, et al. Analysis of efficacy and safety in patients aged 65-75 years at randomization: collaborative atorvastatin diabetes study(CARDS)[J]. Diabetes Care, 2006, 29 (11): 2378-2384. DOI: 10.2337/dc06-0872
|
| [149] |
Bohula E A, Wiviott S D, Giugliano R P, et al. Prevention ofstroke withthe addition ofezetimibeto statin therapy in patients with acute coronary syndrome in IMPROVE-IT (improved reduction of outcomes: Vytorin efficacy international trial)[J]. Circulation, 2017, 136(25): 2440-2450. DOI: 10.1161/CIRCULATIONAHA.117.029095
|
| [150] |
Giugliano R P, Cannon C P, Blazing M A, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT(improved reduction of outcomes: Vytorin efficacy international trial)[J]. Circulation, 2018, 137 (15): 1571-1582. DOI: 10.1161/CIRCULATIONAHA.117.030950
|
| [151] |
McNeil J J, Nelson M R, Woods R L, et al. Effect of aspirin on all-cause mortality in the healthy elderly[J]. N Engl J Med, 2018, 379 (16): 1519-1528. DOI: 10.1056/NEJMoa1803955
|
| [152] |
Wang M, Yu H, Li Z, et al. Benefits andrisks associated with low-dose aspirin use for the primary prevention of cardiovascular disease: a systematic review and Meta analysis of randomized control trials and trial sequential analysis[J]. Am J Cardiovasc Drugs, 2022, 22 (6): 657-675. DOI: 10.1007/s40256-022-00537-6
|
| [153] |
Gu D, Kelly T N, Wu X, et al. Mortality attributable to smoking in China[J]. N Engl J Med, 2009, 360 (2): 150-159. DOI: 10.1056/NEJMsa0802902
|
| [154] |
Chen Z, Peto R, Zhou M, et al. Contrasting male and female trends in tobacco-attributed mortality in China: evidence from successive nationwide prospective cohort studies[J]. Lancet, 2015, 386 (10002): 1447-1456. DOI: 10.1016/S0140-6736(15)00340-2
|
| [155] |
He Y, Lam T H, Jiang B, et al. Passive smoking and risk of peripheral arterial disease andischemic stroke in Chinese women who neversmoked[J]. Circulation, 2008, 118 (15): 1535-1540. DOI: 10.1161/CIRCULATIONAHA.108.784801
|
| [156] |
He Y, Lam T H, J iang B, et al. Combined effects of tobacco smoke exposure and metabolic syndrome on cardiovascularrisk in older residents of China[J]. J Am Coll Cardiol, 2009, 53 (4): 363-371. DOI: 10.1016/j.jacc.2008.08.073
|
| [157] |
Mons U, Müezzinler A, Gellert C, et al. Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium[J]. BMJ, 2015, 350: h1551. DOI: 10.1136/bmj.h1551
|
| [158] |
Villareal D T, Chode S, Parimi N, et al. Weight loss, exercise, or both and physical functionin obese older adults[J]. N Engl J Med, 2011, 364 (13): 1218-1229. DOI: 10.1056/NEJMoa1008234
|
| [159] |
Zhang L, Long J, Jiang W, et al. Trends in chronic kidney diseasein China[J]. N Engl J Med, 2016, 375(9): 905-906. DOI: 10.1056/NEJMc1602469
|
| [160] |
Kidney Disease: Improving Global Outcomes (KDIGO)Diabetes Work Group. KDIGO 2020 clinical practice guidelinefor diabetes management in chronic kidney disease[J]. Kidney Int, 2020, 98 (4S): S1-S115.
|
| [161] |
American Diabetes Association. 11. Microvascular complications andfootcare: standards of medical care in diabetes—2020[J]. Diabetes Care, 2020, 43 (Suppl 1): S135-S151.
|
| [162] |
Yan S T, Liu J Y, Tian H, et al. Clinical and pathological analysis of renal damagein elderly patients with type 2 diabetes mellitus[J]. Clin Exp Med, 2016, 16 (3): 437-442. DOI: 10.1007/s10238-015-0362-5
|
| [163] |
Levey A S, Stevens L A, Schmid C H, et al. A new equation to estimate glomerular filtration rate[J]. Ann Intern Med, 2009, 150 (9): 604-612. DOI: 10.7326/0003-4819-150-9-200905050-00006
|
| [164] |
Guo M, Niu J Y, Ye X W, et al. Evaluation of various equations for estimating renal function in elderly Chinese patients with type 2 diabetes mellitus[J]. Clin Interv Aging, 2017, 12: 1661-1672. DOI: 10.2147/CIA.S140289
|
| [165] |
Mills K T, Chen J, Yang W, et al. Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease[J]. JAMA, 2016 315 (20): 2200-2210. DOI: 10.1001/jama.2016.4447
|
| [166] |
Bakris G L, Agarwal R, Anker S D, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes[J]. N Engl J Med, 2020, 383 (23): 2219-2229. DOI: 10.1056/NEJMoa2025845
|
| [167] |
Zhang H, Xie J, Hao C, et al. Finerenonein patients with chronic kidney disease and type 2 diabetes: the FIDELIODKD subgroup from China[J]. Kidney Dis(Basel), 2023, 9(6): 498-506. DOI: 10.1159/000531997
|
| [168] |
Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with Finerenone in kidney disease and type 2 diabetes[J]. N Engl J Med, 2021, 385 (24): 2252-2263. DOI: 10.1056/NEJMoa2110956
|
| [169] |
Bakris G L, Ruilope L M, Anker S D, et al. A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes[J]. Kidney Int, 2023, 103(1): 196-206. DOI: 10.1016/j.kint.2022.08.040
|
| [170] |
中华医学会糖尿病学分会视网膜病变学组. 糖尿病视网膜病变防治专家共识[J]. 中华糖尿病杂志, 2018, 10 (4): 241-247.
|
| [171] |
Kapoor I, Sarvepalli S M, D' Alessio D, et al. GLP-1 receptor agonists and diabetic retinopathy: a metaanalysis of randomized clinical trials[J]. Surv Ophthalmol, 2023, 68 (6): 1071-1083. DOI: 10.1016/j.survophthal.2023.07.002
|
| [172] |
Bethel M A, Diaz R, Castellana N, et al. HbA(1c)change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a Meta-analysis and Metaregression[J]. Diabetes Care, 2021, 44 (1): 290-296. DOI: 10.2337/dc20-1815
|
| [173] |
Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelinesforthe management of diabetic macular edema by the European Society of Retina Specialists (EURETINA)[J]. Ophthalmologica, 2017, 237 (4): 185-222. DOI: 10.1159/000458539
|
| [174] |
Drinkwater J J, Davis W A, Davis T. A systematic review of risk factors for cataract in type 2 diabetes[J]. Diabetes Metab Res Rev, 2019, 35 (1): e3073. DOI: 10.1002/dmrr.3073
|
| [175] |
GBD 2019 Blindness and Vision Impairment Collaborators, Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to sight: an analysis for the Global Burden of Disease Study[J]. Lancet Glob Health, 2021, 9 (2): e144-e160. DOI: 10.1016/S2214-109X(20)30489-7
|
| [176] |
Song B J, Aiello L P, Pasquale L R. Presence and risk factors for glaucoma in patients with diabetes[J]. Curr Diab Rep, 2016, 16 (12): 124. DOI: 10.1007/s11892-016-0815-6
|
| [177] |
Song P, Xia W, Wang M, et al. Variations of dry eye disease prevalence by age, sex and geographic characteristics in China: a systematic review and meta-analysis[J]. J Glob Health, 2018, 8(2): 020503. DOI: 10.7189/jogh.08.020503
|
| [178] |
Yoo T K, Oh E. Diabetes mellitus is associated with dry eye syndrome: a meta-analysis[J]. Int Ophthalmol, 2019, 39(11): 2611-2620. DOI: 10.1007/s10792-019-01110-y
|
| [179] |
Zou X, Lu L, Xu Y, et al. Prevalence and clinical characteristics of dry eye diseasein community-based type 2 diabetic patients: the Beixinjing eye study[J]. BMC Ophthalmol, 2018, 18 (1): 117. DOI: 10.1186/s12886-018-0781-7
|
| [180] |
The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop(2007)[J]. Ocul Surf, 2007, 5 (2): 75-92. 70081-2.
|
| [181] |
Wu M, Liu X, Han J, et al. Association between sleep quality, moodstatus, and ocular surface characteristicsin patients with dry eye disease[J]. Cornea, 2019, 38 (3): 311-317. DOI: 10.1097/ICO.0000000000001854
|
| [182] |
Pop-Busui R, Evans G W, Gerstein HC, et al. Effects of cardiac autonomic dysfunction on mortality risk in the Actionto Control Cardiovascular Riskin Diabetes (ACCORD) trial[J]. Diabetes Care, 2010, 33 (7): 1578-1584. DOI: 10.2337/dc10-0125
|
| [183] |
Pop-Busui R, Boulton A J, Feldman E L, et al. Diabetic neuropathy: a position statement by the American Diabetes Association[J]. Diabetes Care, 2017, 40(1): 136-154. DOI: 10.2337/dc16-2042
|
| [184] |
Mao F, Zhu X, Liu S, et al. Age as an in dependent risk factor for diabetic peripheral neuropathy in Chinese patients with type 2 diabetes[J]. Aging Dis, 2019, 10(3): 592-600. DOI: 10.14336/AD.2018.0618
|
| [185] |
潘琦, 王晓霞, 王忆力, 等. 北京地区老年糖尿病患者周围神经病变现况调查[J]. 中华老年医学杂志, 2018, 37 (9): 1036-1041. DOI: 10.3760/cma.j.issn.0254-9026.2018.09.020
|
| [186] |
Pan Q, Li Q, Deng W, et al. Prevalence and diagnosis of diabetic cardiovascular autonomic neuropathy in Beijing, China: a retrospective multicenter clinical study[J]. Front Neurosci, 2019, 13 : 1144. DOI: 10.3389/fnins.2019.01144
|
| [187] |
张丽娜, 潘琦, 黄薇, 等. 北京地区2型糖尿病患者糖尿病心脏自主神经病变现况调查[J]. 中华糖尿病杂志, 2021, 13 (6): 570-577. DOI: 10.3760/cma.j.cn115791-20201217-00717
|
| [188] |
Nyiraty S, Pesei F, Orosz A, et al. Cardiovascular autonomic neuropathy and glucose variability in patients with type 1 diabetes: is there an association?[J]. Front Endocrinol(Lausanne), 2018, 9: 174. DOI: 10.3389/fendo.2018.00174
|
| [189] |
Su X, He J, Cui J, et al. The effects of aerobic exercise combined with resistance training on inflammatory factors and heart rate variability in middle-aged and elderly women with type 2 diabetes mellitus[J]. Ann Noninvasive Electrocardiol, 2022, 27 (6): e12996. DOI: 10.1111/anec.12996
|
| [190] |
Arnold A C, Raj S R. Orthostatic hypotension: a practical approach to investigation and management[J]. Can J Cardiol, 2017, 33(12): 1725-1728. DOI: 10.1016/j.cjca.2017.05.007
|
| [191] |
Price R, Smith D, Franklin G, et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: report of the AAN Guideline Subcommittee[J]. Neurology, 2022, 98 (1): 31-43. DOI: 10.1212/WNL.0000000000013038
|
| [192] |
Tesfaye S, Sloan G, Petrie J, et al. Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossovertrial[J]. Lancet, 2022, 400 (10353): 680-690. DOI: 10.1016/S0140-6736(22)01472-6
|
| [193] |
Zhang X, Ran X, Xu Z, et al. Epidemiological characteristics of lower extremity arterial disease in Chinese diabetes patients at high risk: a prospective, multicenter, cross-sectional study[J]. J Diabetes Complications, 2018, 32 (2): 150-156. DOI: 10.1016/j.jdiacomp.2017.10.003
|
| [194] |
Gao Q, He B, Zhu C, et al. Factors associated with lower extremity atherosclerotic disease in Chinese patients with type 2 diabetes mellitus: a case-control study[J]. Medicine(Baltimore), 2016, 95 (51): e5230. DOI: 10.1097/MD.0000000000005230.
|
| [195] |
Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease[J]. N Engl J Med, 1992, 326 (6): 381-386. DOI: 10.1056/NEJM199202063260605
|
| [196] |
林少达, 林楚佳, 王爱红, 等. 中国部分省市糖尿病足调查及神经病变分析[J]. 中华医学杂志, 2007, 87 (18): 1241-1244. DOI: 10.3760/j:issn:0376-2491.2007.18.006
|
| [197] |
许景灿, 王娅平, 陈燕, 等. 基于多中心的中国糖尿病足患者临床资料分析[J]. 中南大学学报(医学版), 2019, 44 (8): 898-904.
|
| [198] |
Ren M, Yang C, Lin D Z, et al. Effect of intensive nursing education on the prevention of diabetic foot ulceration among patients with high-risk diabetic foot: afollow-up analysis[J]. Diabetes Technol Ther, 2014, 16(9): 576-581. DOI: 10.1089/dia.2014.0004
|
| [199] |
Hinchliffe R J, Brownrigg J R, Apelqvist J, et al. IWGDF guidance onthe diagnosis, prognosis and management of peripheral artery disease in patients with foot ulcers in diabetes[J]. Diabetes Metab Res Rev, 2016, 32 Suppl 1: 37-44.
|
| [200] |
Almdal T, Nielsen A A, Nielsen K E, et al. Increased healing in diabetic toe ulcers in a multidisciplinary footclinic: an observational cohort study[J]. DiabetesRes Clin Pract, 2015, 110(3): 315-321. DOI: 10.1016/j.diabres.2015.10.003
|
| [201] |
Whitmer R A, Karter A J, Yaffe K, et al. Hypoglycemic episodesandrisk of dementiain older patients with type 2 diabetes mellitus[J]. JAMA, 2009, 301(15): 1565-1572. DOI: 10.1001/jama.2009.460
|
| [202] |
ElSayed N A, Aleppo G, Aroda V R, et al. 1. Improving care and promoting health in populations: standards of carein diabetes—2023[J]. Diabetes Care, 2023, 46(Supple 1): S10-S18.
|
| [203] |
Yun JS, Ko S H. Risk factors and adverse outcomes of severe hypoglycemiain type 2 diabetes mellitus[J]. Diabetes Metab J, 2016, 40 (6): 423-432. DOI: 10.4093/dmj.2016.40.6.423
|
| [204] |
Pi-tkiewicz P, Buraczewska-Leszczyńska B, Kuczerowski R, et al. Severe hypoglycaemiainelderly patients with type 2 diabetes and coexistence of cardiovascular history[J]. Kardiol Pol, 2016, 74(8): 779-785. DOI: 10.5603/KP.a2016.0043
|
| [205] |
Freeman J. Management of hypoglycemiain older adults with type2 diabetes[J]. Postgrad Med, 2019, 131 (4): 241-250. DOI: 10.1080/00325481.2019.1578590
|
| [206] |
Punthakee Z, Miller M E, Launer L J, et al. Poor cognitive function and risk of severe hypoglycemiain type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial[J]. Diabetes Care, 2012, 35 (4): 787-793. DOI: 10.2337/dc11-1855
|
| [207] |
Hope SV, Taylor PJ, Shields BM, et al. Are we missing hypoglycaemia- Elderly patients with insulin treated diabetes present to primary care frequently with non-specific symptoms associated with hypoglycaemia[J]. Prim Care Diabetes, 2018, 12 (2): 139-146. DOI: 10.1016/j.pcd.2017.08.004
|
| [208] |
Stahn A, Pistrosch F, Ganz X, et al. Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias[J]. Diabetes Care, 2014, 37 (2): 516-520. DOI: 10.2337/dc13-0600
|
| [209] |
Heller S R, Cryer P E. Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans[J]. Diabetes, 1991, 40 (2): 223-226. DOI: 10.2337/diab.40.2.223
|
| [210] |
Seaquist E R, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society[J]. Diabetes Care, 2013, 36 (5): 1384-1395. DOI: 10.2337/dc12-2480
|
| [211] |
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas orinsulin compared with conventional treatment and risk ofcomplicationsin patients with type 2 diabetes (UKPDS 33)[J]. Lancet, 1998, 352(9131): 837-853. DOI: 10.1016/S0140-6736(98)07019-6
|
| [212] |
Polonsky W H, Peters A L, Hessler D. The impact of real-time continuous glucose monitoring in patients 65 years and older[J]. J Diabetes Sci Technol, 2016, 10(4): 892-897. DOI: 10.1177/1932296816643542
|
| [213] |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中华糖尿病杂志, 2018, 10(1): 4-67. DOI: 10.3760/cma.j.issn.1674-5809.2018.01.003
|
| [214] |
Abdelhafiz A H, Rodríguez-Ma-as L, MorleyJ E, et al. Hypoglycemia in older people—a less well recognized risk factor for frailty[J]. Aging Dis, 2015, 6(2): 156-167. DOI: 10.14336/AD.2014.0330
|
| [215] |
Bonds D E, Kurashige E M, Bergenstal R, et al. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Riskin Diabetes (ACCORD)trial[J]. Am J Cardiol, 2007, 99 (12A): 80i-89i.
|
| [216] |
Lipska K J, Krumholz H, Soones T, et al. Polypharmacy in the aging patient: a review of glycemic controlin older adults with type 2 diabetes[J]. JAMA, 2016, 315 (10): 1034-1045. DOI: 10.1001/jama.2016.0299
|
| [217] |
Weinstock R S, Xing D, Maahs D M, et al. Severe hypoglycemia and diabetic ketoacidosisin adults with type 1 diabetes: resultsfromthe T1D Exchange clinic registry[J]. J Clin Endocrinol Metab, 2013, 98 (8): 3411-3419. DOI: 10.1210/jc.2013-1589
|
| [218] |
Pratley RnE, Kanapka L G, Rickels M R, et al. Effect of continuous glucose monitoring on hypoglycemia in older adults with type 1 diabetes: a randomized clinicaltrial[J]. JAMA, 2020, 323 (23): 2397-2406. DOI: 10.1001/jama.2020.6928
|
| [219] |
Kitabchi A E, Umpierrez G E, Miles J M, et al. Hyperglycemic crises in adult patients with diabetes[J]. Diabetes Care, 2009, 32 (7): 1335-1343. DOI: 10.2337/dc09-9032
|
| [220] |
Kitabchi A E, Umpierrez G E, Murphy M B, et al. Management of hyperglycemic crisesin patients with diabetes[J]. Diabetes Care, 2001, 24 (1): 131-153. DOI: 10.2337/diacare.24.1.131
|
| [221] |
Malone M L, Gennis V, Goodwin J S. Characteristics of diabetic ketoacidosis in older versus younger adults[J]. J Am Geriatr Soc, 1992, 40 (11): 1100-1104. DOI: 10.1111/j.1532-5415.1992.tb01797.x
|
| [222] |
Wu L, Tsang V, Menzies A M, et al. Risk factors and characteristics of checkpoint inhibitor-associated autoimmune diabetes mellitus(CIADM): a systematic review and delineation from type 1 diabetes[J]. Diabetes Care, 2023, 46 (6): 1292-1299. DOI: 10.2337/dc22-2202
|
| [223] |
Zhang W, Chen J, Bi J, et al. Combined diabetic ketoacidosis and hyperosmolar hyperglycemic statein type 1 diabetes mellitus induced by immune checkpoint inhibitors: underrecognized and underreported emergency in ICIs-DM[J]. Front Endocrinol(Lausanne), 2022, 13: 1084441.
|
| [224] |
Goldman A, Fishman B, Twig G, et al. The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥-75 years): a retrospective, pharmacovigilancestudy[J]. Cardiovasc Diabetol, 2023, 22(1): 16. DOI: 10.1186/s12933-023-01743-5
|
| [225] |
Bertoni A G, Hundley W G, Massing M W, et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes[J]. Diabetes Care, 2004, 27 (3): 699-703. DOI: 10.2337/diacare.27.3.699
|
| [226] |
Papakitsou I, Mavrikaki V, Petrakis E, et al. High incidence of heart failure in elderly patients with diabetes admitted in internal medicine department[J]. Atherosclerosis, 2021(331): e241.
|
| [227] |
Boonman-de Winter L J, Rutten F H, Cramer M J, et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes[J]. Diabetologia, 2012, 55 (8): 2154-2162. DOI: 10.1007/s00125-012-2579-0
|
| [228] |
Cavender M A, Steg P G, Smith S C Jr, et al. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the reduction of atherothrombosis for continued health(REACH)registry[J]. Circulation, 2015, 132(10): 923-931. DOI: 10.1161/CIRCULATIONAHA.114.014796
|
| [229] |
Scirica B M, Bhatt D L, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus[J]. N Engl J Med, 2013, 369 (14): 1317-1326. DOI: 10.1056/NEJMoa1307684
|
| [230] |
Eurich D T, Weir D L, Majumdar S R, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34, 000 patients[J]. Circ Heart Fail, 2013, 6 (3): 395-402. DOI: 10.1161/CIRCHEARTFAILURE.112.000162
|
| [231] |
Tseng C H. Metformin useis associated with alower risk of hospitalization for heart failure in patients with type 2 diabetes mellitus: a retrospective cohort analysis[J]. J Am Heart Assoc, 2019, 8 (21): e011640. DOI: 10.1161/JAHA.118.011640
|
| [232] |
中华医学会糖尿病学分会, 中华医学会内分泌学分会. 中国成人2型糖尿病合并心肾疾病患者降糖药物临床应用专家共识[J]. 中华糖尿病杂志, 2020, 12(6): 369-381. DOI: 10.3760/cma.j.cn115791-20200419-00233
|
| [233] |
Kutz A, Kim D H, Wexler D J, et al. Comparative cardiovascular effectiveness and safety of SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors according to frailty in type 2 diabetes[J]. Diabetes Care, 2023, 46(11): 2004-2014. DOI: 10.2337/dc23-0671
|
| [234] |
Ling X, Cummings SR, Mingwei Q, et al. Vertebral fractures in Beijing, China: the Beijing OsteoporosisProject[J]. J Bone Miner Res, 2000, 15 (10): 2019-2025. DOI: 10.1359/jbmr.2000.15.10.2019
|
| [235] |
Gilbert M P, Pratley R E. The impact of diabetes and diabetes medications on bone health[J]. Endocr Rev, 2015, 36(2): 194-213. DOI: 10.1210/er.2012-1042
|
| [236] |
Pan Q, Chen H, Fei S, et al. Medications and medical expenditures for diabetic patients with osteoporosis in Beijing, China: a retrospective study[J]. Diabetes Res Clin Pract, 2023, 206: 110980. DOI: 10.1016/j.diabres.2023.110980
|
| [237] |
Dufour A B, Kiel D P, Williams S A, et al. Risk factors for incident fracture in older adults with type 2 diabetes: the Framingham Heart Study[J]. Diabetes Care, 2021, 44(7): 1547-1555. DOI: 10.2337/dc20-3150
|
| [238] |
Bonds D E, Larson J C, Schwartz A V, et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study[J]. J Clin Endocrinol Metab, 2006, 91 (9): 3404-3410. DOI: 10.1210/jc.2006-0614
|
| [239] |
Giangregorio L M, Leslie W D, Lix L M, et al. FRAX underestimates fracture risk in patients with diabetes[J]. J Bone Miner Res, 2012, 27 (2): 301-308. DOI: 10.1002/jbmr.556
|
| [240] |
Tao Y, Meng E, ShiJ, e tal. Sulfonylureas use and fractures riskin elderly patients with type 2 diabetes mellitus: a meta-analysisstudy[J]. Aging Clin Exp Res, 2021, 33(8): 2133-2139. DOI: 10.1007/s40520-020-01736-4
|
| [241] |
中华医学会骨质疏松和骨矿盐疾病分会, 中华医学会内分泌学分会, 中华医学会糖尿病学分会, 等. 糖尿病患者骨折风险管理中国专家共识[J]. 中华糖尿病杂志, 2019, 11 (7): 445-456. DOI: 10.3760/cma.j.issn.1674-5809.2019.07.002
|
| [242] |
Won C W, Yoo H J, Yu S H, et al. Lists of geriatric syndromes in the Asian-Pacific Geriatric Societies[J]. Eur Geriatr Med, 2013, 4(5): 335-338. DOI: 10.1016/j.eurger.2013.07.005
|
| [243] |
Wang T, Feng X, Zhou J, et al. Type 2 diabetes mellitus is associated with increased risks of sarcopenia and pre-sarcopeniain Chinese elderly[J]. Sci Rep, 2016, 6 : 38937. DOI: 10.1038/srep38937
|
| [244] |
Leenders M, Verdijk L B, van der Hoeven L, et al. Patients with type 2 diabetes show a greater decline in muscle mass, muscle strength, and functional capacity with aging[J]. J Am Med Dir Assoc, 2013, 14 (8): 585-592. DOI: 10.1016/j.jamda.2013.02.006
|
| [245] |
Mori H, Kuroda A, Araki M, et al. Advanced glycation end-products areariskfor muscle weaknessin Japanese patients with type 1 diabetes[J]. J Diabetes Investig, 2017, 8(3): 377-382. DOI: 10.1111/jdi.12582
|
| [246] |
An H J, Tizaoui K, Terrazzino S, et al. Sarcopenia in autoimmune andrheumatic diseases: a comprehensive review[J]. Int J Mol Sci, 2020, 21 (16): 5678. DOI: 10.3390/ijms21165678
|
| [247] |
何清华, 孙明晓, 岳燕芬, 等. 老年糖尿病肌少症患者的代谢特点及膳食分析[J]. 中华老年医学杂志, 2019, 38 (5): 552-557. DOI: 10.3760/cma.j.issn.0254-9026.2019.05.019
|
| [248] |
Kalyani R R, Corriere M, Ferrucci L. Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases[J]. Lancet Diabetes Endocrinol, 2014, 2 (10): 819-829. DOI: 10.1016/S2213-8587(14)70034-8
|
| [249] |
Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies[J]. Nat Rev Endocrinol, 2018, 14 (9): 513-537. DOI: 10.1038/s41574-018-0062-9
|
| [250] |
Batsis J A, Mackenzie T A, Emeny R T, et al. Low lean mass with and without obesity, and mortality: results from the 1999—2004 national health and nutrition examination survey[J]. J Gerontol A Biol Sci Med Sci, 2017, 72(10): 1445-1451. DOI: 10.1093/gerona/glx002
|
| [251] |
Chen L K, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment[J]. J Am Med Dir Assoc, 2020, 21(3): 300-307. e2. DOI: 10.1016/j.jamda.2019.12.012
|
| [252] |
Hanlon P, Nicholl B I, Jani B D, et al. Frailty and prefrailty in middle-aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493-737 UK Biobank participants[J]. Lancet Public Health, 2018, 3 (7): e323-e332. DOI: 10.1016/S2468-2667(18)30091-4
|
| [253] |
Kong L N, Lyu Q, Yao H Y, et al. The prevalence of frailty among community-dwelling older adults with diabetes: a meta-analysis[J]. Int J Nurs Stud, 2021, 119: 103952. DOI: 10.1016/j.ijnurstu.2021.103952
|
| [254] |
Strain W D, Down S, Brown P, et al. Diabetes and frailty: an expert consensus statement on the management of older adults with type 2 diabetes[J]. Diabetes Ther, 2021, 12 (5): 1227-1247. DOI: 10.1007/s13300-021-01035-9
|
| [255] |
Rodriguez-Ma-as L, Laosa O, Vellas B, et al. Effectiveness of a multimodal intervention in functionally impaired older people with type 2 diabetes mellitus[J]. J Cachexia Sarcopenia Muscle, 2019, 10(4): 721-733. DOI: 10.1002/jcsm.12432
|
| [256] |
Umegaki H. Sarcopenia and frailty in older patients with diabetes mellitus[J]. Geriatr GerontolInt, 2016, 16(3): 293-299.
|
| [257] |
Yang Y, Hu X, Zhang Q, et al. Diabetes mellitus and risk of falls in older adults: a systematic review and meta-analysis[J]. Age Ageing, 2016, 45 (6): 761-767. DOI: 10.1093/ageing/afw140
|
| [258] |
Chen J F, Zhang Y P, Han J X, et al. Systematic evaluation of the prevalence of cognitive impairment in elderly patients with diabetes in China[J]. Clin Neurol Neurosurg, 2023, 225 : 107557. DOI: 10.1016/j.clineuro.2022.107557
|
| [259] |
Cukierman-Yaffe T, Gerstein H C, Williamson J D, et al. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND)trial[J]. Diabetes Care, 2009, 32(2): 221-226. DOI: 10.2337/dc08-1153
|
| [260] |
Cukierman T, Gerstein H C, Williamson J D. Cognitive decline and dementia in diabetes--systematic overview of prospective observational studies[J]. Diabetologia, 2005, 48(12): 2460-2469. DOI: 10.1007/s00125-005-0023-4
|
| [261] |
Tomlin A, Sinclair A. The influence of cognition on self-management of type 2 diabetes in older people[J]. Psychol Res Behav Manag, 2016, 9: 7-20.
|
| [262] |
Folstein M F, Folstein S E, McHugh P R. " Mini-mental state". A practical method for grading the cognitive state of patients for the clinician[J]. J Psychiatr Res, 1975, 12(3): 189-198. DOI: 10.1016/0022-3956(75)90026-6
|
| [263] |
Nasreddine Z S, Phillips N A, Bédirian V, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment[J]. J Am Geriatr Soc, 2005, 53(4): 695-699. DOI: 10.1111/j.1532-5415.2005.53221.x
|
| [264] |
Sun M, Chen W M, Wu SY, et al. Metformin in elderly type 2 diabetes mellitus: dose-dependent dementia risk reduction[J]. Brain, 2023 : awad366.
|
| [265] |
Zhou B, Zissimopoulos J, Nadeem H, et al. Association between exenatide use and incidence of Alzheimer's disease[J]. Alzheimers Dement (N Y), 2021, 7(1): e12139. DOI: 10.1002/trc2.12139
|
| [266] |
Yang Y, Zhao J J, Yu X F. Expert consensus on cognitive dysfunctionin diabetes[J]. Curr Med Sci, 2022, 42 (2): 286-303. DOI: 10.1007/s11596-022-2549-9
|
| [267] |
Chen Y, Qin J, Tao L, et al. Effects of Tai Chi Chuan on cognitive function in adults 60 years or older with type 2 diabetes and mild cognitive impairment in China: a randomized clinical trial[J]. JAMA Netw Open, 2023, 6 (4): e237004. DOI: 10.1001/jamanetworkopen.2023.7004
|
| [268] |
Alvarez-Cisneros T, Roa-Rojas P, Garcia-Pe-a C. Longitudinal relationship of diabetes and depressive symptoms in older adults from Mexico: a secondary data analysis[J]. BMJ Open Diabetes Res Care, 2020, 8(2): e001789. DOI: 10.1136/bmjdrc-2020-001789
|
| [269] |
Mendes R, Martins S, Fernandes L. Adherence to medication, physical activity and diet in older adults with diabetes: its association with cognition, anxiety and depression[J]. J Clin Med Res, 2019, 11 (8): 583-592. DOI: 10.14740/jocmr3894
|
| [270] |
Kukreja D, Günther U, Popp J. Delirium in the elderly: current problems withincreasing geriatricage[J]. Indian J Med Res, 2015, 142 (6): 655-662. DOI: 10.4103/0971-5916.174546
|
| [271] |
O' Brien H, Anne Kenny R. Syncope in the elderly[J]. Eur Cardiol, 2014, 9 (1): 28-36. DOI: 10.15420/ecr.2014.9.1.28
|
| [272] |
Ooi W L, Hossain M, Lipsitz L A. The association between orthostatic hypotension and recurrent falls in nursing home residents[J]. Am J Med, 2000, 108(2): 106-111. DOI: 10.1016/S0002-9343(99)00425-8
|
| [273] |
Masaki K H, Schatz I J, Burchfiel C M, et al. Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program[J]. Circulation, 1998, 98 (21): 2290-2295. DOI: 10.1161/01.CIR.98.21.2290
|
| [274] |
Xin W, Lin Z, Mi S. Orthostatic hypotension and mortalityrisk: a meta-analysis of cohort studies[J]. Heart, 2014, 100(5): 406-413. DOI: 10.1136/heartjnl-2013-304121
|
| [275] |
Shibao C, Grijalva C G, Raj S R, et al. Orthostatic hypotension-related hospitalizations in the United States[J]. Am J Med, 2007, 120 (11): 975-980. DOI: 10.1016/j.amjmed.2007.05.009
|
| [276] |
Di Stefano C, Milazzo V, Totaro S, et al. Orthostatic hypotension in a cohort of hypertensive patients referring to a hypertension clinic[J]. J Hum Hypertens, 2015, 29 (10): 599-603. DOI: 10.1038/jhh.2014.130
|
| [277] |
Kamaruzzaman S, Watt H, Carson C, et al. The association between orthostatic hypotension and medication use in the British Women's Heart and Health Study[J]. Age Ageing, 2010, 39 (1): 51-56. DOI: 10.1093/ageing/afp192
|
| [278] |
Maurer MS, Karmally W, Rivadeneira H, et al. Upright posture and postprandial hypotensionin elderly persons[J]. Ann Intern Med, 2000, 133 (7): 533-536. DOI: 10.7326/0003-4819-133-7-200010030-00012
|
| [279] |
Shibao C, Gamboa A, Diedrich A, et al. Acarbose, an alphaglucosidase inhibitor, attenuates postprandial hypotension in autonomic failure[J]. Hypertension, 2007, 50(1): 54-61. DOI: 10.1161/HYPERTENSIONAHA.107.091355
|
| [280] |
Sacerdote C, Ricceri F. Epidemiological dimensions of the association between type 2 diabetes and cancer: a review of observational studies[J]. Diabetes Res ClinPract, 2018, 143 : 369-377.
|
| [281] |
Carstensen B, Read S H, Friis S, et al. Cancer incidence in persons with type 1 diabetes: a fivecountry study of 9, 000 cancers in type 1 diabetic individuals[J]. Diabetologia, 2016, 59 (5): 980-988. DOI: 10.1007/s00125-016-3884-9
|
| [282] |
Orchard S G, LockeryJ E, Broder J C, et al. Association of metformin, aspirin, and cancer incidence with mortality riskin adults with diabetes[J]. JNCI Cancer Spectr, 2023, 7(2): pkad017. DOI: 10.1093/jncics/pkad017
|
| [283] |
Li Z, Lin C, Zhou J, et al. Dipeptidyl peptidase 4- inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 participants[J]. Expert Opin Investig Drugs, 2022, 31 (9): 957-964. DOI: 10.1080/13543784.2022.2113056
|
| [284] |
Fietze I, Laharnar N, Obst A, et al. Prevalence and association analysis of obstructive sleep apnea with gender and age differences-Results of SHIP-Trend[J]. J Sleep Res, 2019, 28(5): e12770. DOI: 10.1111/jsr.12770
|
| [285] |
Nagayoshi M, Punjabi N M, Selvin E, et al. Obstructive sleep apnea and incident type 2 diabetes[J]. Sleep Med, 2016, 25: 156-161. DOI: 10.1016/j.sleep.2016.05.009
|
| [286] |
中国医师协会睡眠医学专业委员会. 成人阻塞性睡眠呼吸暂停多学科诊疗指南[J]. 中华医学杂志, 2018, 98(24): 1902-1914. DOI: 10.3760/cma.j.issn.0376-2491.2018.24.003
|
| [287] |
Chen L, Pei J H, Chen H M. Effects of continuous positive airway pressure treatment on glycaemic control and insulin sensitivity in patients with obstructive sleep apnoea and type 2 diabetes: a metaanalysis[J]. Arch Med Sci, 2014, 10 (4): 637-642.
|
| [288] |
Guo LX, Zhao X, Pan Q, et al. Effect of continuous positive airway pressure therapy on glycemic excursions and insulin sensitivity in patients with obstructive sleep apnea-hypopnea syndrome and type 2 diabetes[J]. Chin Med J (Engl), 2015, 128 (17): 2301-2306. DOI: 10.4103/0366-6999.163382
|
| [289] |
中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 成人阻塞性睡眠呼吸暂停基层诊疗指南(2018年)[J]. 中华全科医师杂志, 2019, 18(1): 21-29. DOI: 10.3760/cma.j.issn.1671-7368.2019.01.007
|
| [290] |
Gordon N P, Yao JH, Brickner L A, et al. Prevalence of sleep-related problems and risks in a communitydwelling older adult population: a cross-sectional survey-based study[J]. BMC Public Health, 2022, 22(1): 2045. DOI: 10.1186/s12889-022-14443-8
|
| [291] |
Li M, Li D, Tang Y, et al. Effect of diabetes sleep educationfor T2DM who sleep after midnight: a pilot study from China[J]. Metab Syndr Relat Disord, 2018, 16(1): 13-19. DOI: 10.1089/met.2017.0069
|
| [292] |
Wu C Z, Yuan Y H, Liu H H, et al. Epidemiologic relationship between periodontitis andtype 2 diabetes mellitus[J]. BMC Oral Health, 2020, 20 (1): 204. DOI: 10.1186/s12903-020-01180-w
|
| [293] |
Casanova L, Hughes F J, Preshaw P M. Diabetes and periodontal disease: a two-way relationship[J]. Br Dent J, 2014, 217 (8): 433-437. DOI: 10.1038/sj.bdj.2014.907
|
| [294] |
Rapone B, Ferrara E, Corsalini M, et al. The effect of gaseous ozone therapy in conjunction with periodontal treatment on glycated hemoglobin level in subjects with type 2 diabetes mellitus: an unmasked randomized controlled trial[J]. Int J Environ Res Public Health, 2020, 17(15): 5467. DOI: 10.3390/ijerph17155467
|
| [295] |
Demmer R T, Jacobs D R Jr, Desvarieux M. Periodontal disease and incident type 2 diabetes: results from the First National Health and Nutrition Examination Survey and its epidemiologic follow-up study[J]. Diabetes Care, 2008, 31 (7): 1373-1379. DOI: 10.2337/dc08-0026
|
| [296] |
Yamaoka H, Sasaki H, Yamasaki H, et al. Truncal pruritus of unknown origin may be a symptom of diabetic polyneuropathy[J]. Diabetes Care, 2010, 33 (1): 150-155. DOI: 10.2337/dc09-0632
|
| [297] |
Yang Q P, Chen Y Y, Li Z, et al. Major risk factors analysis of pruritus complicated by type 2 diabetes mellitus and the effect of comprehensive nursing intervention[J]. Front Surg, 2022, 9 : 842884. DOI: 10.3389/fsurg.2022.842884
|
| [298] |
Park J Y, Kim K A, Kang M H, et al. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects[J]. Clin Pharmacol Ther, 2004, 75 (3): 157-162. DOI: 10.1016/j.clpt.2003.10.003
|
| [299] |
Brown N J, Byiers S, Carr D, et al. Dipeptidyl peptidase-Ⅳ inhibitor use associated with increased risk of ACE inhibitor-associated angioedema[J]. Hypertension, 2009, 54 (3): 516-523. DOI: 10.1161/HYPERTENSIONAHA.109.134197
|
| [300] |
Backman J T, Filppula A M, Niemi M, et al. Role of cytochrome P450 2C8 in drug metabolism and interactions[J]. Pharmacol Rev, 2016, 68 (1): 168-241. DOI: 10.1124/pr.115.011411
|
| [301] |
Umpierrez G E, Pasquel F J. Management of inpatient hyperglycemiaand diabetes in older adults[J]. Diabetes Care, 2017, 40(4): 509-517. DOI: 10.2337/dc16-0989
|
| [302] |
中国医师协会内分泌代谢科医师分会; 中国住院患者血糖管理专家组. 中国住院患者血糖管理专家共识[J]. 中华内分泌代谢杂志, 2017, 33 (1): 1-10. DOI: 10.3760/cma.j.issn.1000-6699.2017.01.001
|
| [303] |
Diabetic diets for frail elderly long-term care residents with type Ⅱdiabetes mellitus: a review of guidelines[EB/OL]. (2015-06-15)[2021-11-01]. https://www.ncbi.nlm.nih.gov/books/NBK304586/.
|
| [304] |
王双, 詹俊鲲, 程梅, 等. 中国养老机构内老年人血糖规范化管理专家共识(2021)[J]. 中华老年医学杂志, 2021, 40 (6): 683-694. DOI: 10.3760/cma.j.issn.0254-9026.2021.06.001
|
| [305] |
李杨, 黄丹, 刘彤, 等. 老年糖尿病患者生活质量相关因素的研究现状[J]. 中国老年学杂志, 2015, (14): 4090-4092. DOI: 10.3969/j.issn.1005-9202.2015.14.151
|
| [306] |
王莹, 蔡玉萍, 许新华, 等. 多学科团队模式在居家老年糖尿病患者血糖管理中的应用[J]. 世界最新医学信息文摘(连续型电子期刊), 2019, 19 (8): 288-289.
|
| [307] |
中华医学会麻醉学分会. 围术期血糖管理专家共识(快捷版)[J]. 临床麻醉学杂志, 2016, 32(1): 93-95.
|
| [308] |
Umpierrez G, Cardona S, Pasquel F, et al. Randomized controlled trial of intensive versus conservative glucose control in patients undergoing coronary artery bypass graft surgery: GLUCO-CABG trial[J]. Diabetes Care, 2015, 38(9): 1665-1672. DOI: 10.2337/dc15-0303
|
| [309] |
Jinjing W, Kang C, Xufei L, et al. Chinese clinical practice guidelines for perioperative blood glucose management[J]. Diabetes Metab Res Rev, 2021, 37(7): e3439. DOI: 10.1002/dmrr.3439
|
| [310] |
Muller L M, Gorter K J, Hak E, et al. Increased risk of commoninfectionsin patients with type 1 and type 2 diabetes mellitus[J]. Clin Infect Dis, 2005, 41 (3): 281-288. DOI: 10.1086/431587
|
| [311] |
Polk C, Sampson M M, Roshdy D, et al. Skin and soft tissue infections in patients with diabetes mellitus[J]. Infect Dis Clin North Am, 2021, 35(1): 183-197. DOI: 10.1016/j.idc.2020.10.007
|
| [312] |
Pearson-Stuttard J, Blundell S, Harris T, et al. Diabetes and infection: assessing the association with glycaemic control in population-based studies[J]. Lancet Diabetes Endocrinol, 2016, 4 (2): 148-158. DOI: 10.1016/S2213-8587(15)00379-4
|
| [313] |
Carey I M, Critchley J A, DeWilde S, et al. Risk of infectionintype1 and type 2 diabetes compared with the general population: a matched cohort study[J]. Diabetes Care, 2018, 41(3): 513-521. DOI: 10.2337/dc17-2131
|
| [314] |
Li H, Tian S, Chen T, et al. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetesin hospitalized patients with COVID-19[J]. Diabetes Obes Metab, 2020, 22 (10): 1897-1906. DOI: 10.1111/dom.14099
|
| [315] |
Khunti K, Del Prato S, Mathieu C, et al. COVID-19, hyperglycemia, and new-onset diabetes[J]. Diabetes Care, 2021, 44 (12): 2645-2655. DOI: 10.2337/dc21-1318
|
| [316] |
Rondy M, El Omeiri N, Thompson MG, et al. Effectiveness of influenza vaccines in preventing severe influenza illness among adults: a systematic review and meta-analysis of test-negative design casecontrol studies[J]. J Infect, 2017, 75 (5): 381-394. DOI: 10.1016/j.jinf.2017.09.010
|
| [317] |
Niu X, Luo S, Li X, et al. Identification of a distinct phenotype of elderly latent autoimmune diabetes in adults: LADA China Study 8[J]. Diabetes Metab Res Rev, 2019, 35(1): e3068. DOI: 10.1002/dmrr.3068
|
| [318] |
Munshi M, Slyne C, Davis D, et al. Use oftechnologyin older adults with type 1 diabetes: clinical characteristics and glycemic metrics[J]. Diabetes Technol Ther, 2022, 24(1): 1-9. DOI: 10.1089/dia.2021.0246
|
| [319] |
Miller KnM, Kanapka L G, Rickels M R, et al. Benefit of continuous glucose monitoring in reducing hypoglycemiais sustained through 12 months of use among older adults with type 1 diabetes[J]. Diabetes Technol Ther, 2022, 24 (6): 424-434. DOI: 10.1089/dia.2021.0503
|
| [320] |
Boughton CK, Hartnell S, Thabit H, et al. Hybridclosed-loop glucose control compared with sensor augmented pumptherapyin older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study[J]. Lancet Healthy Longev, 2022, 3(3): e135-e142. DOI: 10.1016/S2666-7568(22)00005-8
|
| [321] |
Ruedy K J, Parkin C G, Riddlesworth T D, et al. Continuous glucose monitoring in older adults with type 1 and type 2 diabetes using multiple daily injections of insulin: resultsf rom the DIAMOND trial[J]. J Diabetes Sci Technol, 2017, 11 (6): 1138-1146. DOI: 10.1177/1932296817704445
|
| [322] |
Vigersky R A, Fonda S J, Chellappa M, et al. Short-and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes[J]. Diabetes Care, 2012, 35 (1): 32-38. DOI: 10.2337/dc11-1438
|
| [323] |
Bao S, Bailey R, Calhoun P, et al. Effectiveness of continuous glucose monitoring in older adults with type 2 diabetes treated with basal insulin[J]. Diabetes Technol Ther, 2022, 24 (5): 299-306. DOI: 10.1089/dia.2021.0494
|
| [324] |
Lu J, Ma X, Zhou J, et al. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes[J]. Diabetes Care, 2018, 41 (11): 2370-2376. DOI: 10.2337/dc18-1131
|
| [325] |
Lu J, Wang C, Shen Y, et al. Time in range in relation to all-cause and cardiovascular mortality in patients with type 2 diabetes: a prospective cohort study[J]. Diabetes Care, 2021, 44 (2): 549-555. DOI: 10.2337/dc20-1862
|
| [326] |
O'Neal D N, Cohen O, Vogrin S, et al. An assessment of clinical continuous glucose monitoring targets for older and high-risk peopleliving with type 1 diabetes[J]. Diabetes Technol Ther, 2023, 25 (2): 108-115. DOI: 10.1089/dia.2022.0350
|
| [327] |
Huang E S, Sinclair A, Conlin P R, et al. The growing role of technology in the care of older adults with diabetes[J]. Diabetes Care, 2023, 46 (8): 1455-1463. DOI: 10.2337/dci23-0021
|
| [328] |
Frid A H, Kreugel G, Grassi G, et al. New insulin delivery recommendations[J]. Mayo Clin Proc, 2016, 91 (9): 1231-1255. DOI: 10.1016/j.mayocp.2016.06.010
|
| [329] |
Guo L, Zhang Q, Xue Y, et al. A nationwide crosssectional survey of knowledge and practices of diabetes drug injection techniques of patients, nurses, and physicians: the China IT improve study[J]. Mayo Clin Proc, 2023, 98 (10): 1482-1500. DOI: 10.1016/j.mayocp.2023.02.010
|
| [330] |
罗樱樱, 张明霞, 纪立农. 内分泌科医生及糖尿病患者对新型记忆功能胰岛素笔的评价性研究[J]. 中国糖尿病杂志, 2014, 22 (6): 533-541. DOI: 10.3969/j.issn.1006-6187.2014.06.015
|
| [331] |
Adolfsson P, Hartvig N V, Kaas A, et al. Increased time in range and fewer missed bolus injections after introduction of a smart connected insulin pen[J]. Diabetes Technol Ther, 2020, 22 (10): 709-718. DOI: 10.1089/dia.2019.0411
|
| [332] |
Ji L, Gao L, Chen L, et al. Insulin delivery with a needle-free insulin injector versus a conventional insulin pen in Chinese patients with type 2 diabetes mellitus: a 16-week, multicenter, randomized clinical trial(the FREE study)[J]. EClinicalMedicine, 2020, 23: 100368. DOI: 10.1016/j.eclinm.2020.100368
|
| [333] |
Herman W H, Ilag L L, Johnson S L, et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes[J]. Diabetes Care, 2005, 28 (7): 1568-1573. DOI: 10.2337/diacare.28.7.1568
|
| [334] |
Davis G M, Peters A L, Bode B W, et al. Safety and efficacy of the omnipod 5 automated insulin delivery systemin adults with type 2 diabetes: from injections to hybrid closed-loop therapy[J]. Diabetes Care, 2023, 46(4): 742-750. DOI: 10.2337/dc22-1915
|
| [335] |
Stephens E A, Heffner J. Evaluating older patients with diabetes for insulin pump therapy[J]. Diabetes Technol Ther, 2010, 12 Suppl 1: S91-S97.
|
| 1. |
高一城，于子津，曹蕊，刘芷含，方锐，李媛媛，邓迎杰，向文远，费宇彤. 实证研究在临床实践指南制订中的思考及方法学建议. 中国全科医学. 2025(04): 402-406 .
| |
| 2. |
田晨，晏毅龙，王勇，童博，田金徽，葛龙. 证据智能合成与分级：AutoMeta平台开发与验证. 中国循证医学杂志. 2024(04): 459-465 .
| |
| 3. |
黄嘉杰，赖鸿皓，刘佳宁，赵威龙，孙铭谣，叶紫莹，李颖，潘蓓，田金徽，栗梦婷，葛龙. 网状Meta分析证据确信度分级与结果解读：方法与案例. 中国循证医学杂志. 2024(10): 1231-1240 .
| |
| 4. |
刘芳绮，刘孟宇，郑丹平，李安，陈雪，张格知，卫东锋，杨伟，柏伟宣，李勇. 基于AGREE-HS评价的应急卫生系统指南可实施性特点. 中国实验方剂学杂志. 2024(24): 250-256 .
| |
| 5. |
李苗苗，王文雅，李雅婧，赵晖，廖星. 中医药快速综述实施报告规范的制定与条目清单. 中国中药杂志. 2024(21): 5951-5957 .
|
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Submit
Review
Office
Email Alert
RSS
DownLoad: